Two Harvard medical school professors are suing the Trump administration, arguing that their research was unfairly removed from a government-run website.

Mirvetuximab soravtansine improved overall survival over chemotherapy in patients with FRα-positive, platinum-resistant ovarian cancer.

Combination treatment with cadonilimab and lenvatinib can produce responses in patients with advanced endometrial cancer.

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

Adjuvant CRT did not improve outcomes over adjuvant RT in patients with intermediate-risk, early-stage cervical cancer after radical hysterectomy.

Adding pembrolizumab to CCRT improved survival outcomes in patients with high-risk, locally advanced cervical cancer.

A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer in a first-in-human trial. These results were presented at ...

From 1990 to 2023, there was a decrease in the number of births, general fertility rates, and total fertility rates in the United States.

The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

In honor of Women’s History Month, test your knowledge about these pioneering figures and their achievements. This quiz originally appeared on MPR.

The prospect of deep Medicaid cuts has become a flashpoint in Congress, with leaders of both parties accusing their counterparts of lying.

Although the tilsotolimod plus ipilimumab treatment did not meet its co-primary endpoint, these results are a valuable addition to the literature with respect to second-line treatment options in this ...